“Activartis is a biotech company based in Vienna and is developing a novel cancer immunotherapy concept in phase II clinical trial. Currently directed against aggressive brain cancer, it will in principle be applicable against all types of cancerous diseases. The therapeutic platform combines a completely novel, proprietary
approach by utilising a bacterial danger signal in combination with the patient’s tumour antigens together with the proven successful concept of dendritic cells to
mobilise the patients’ immune system to combat the disease.”
